

Opioids

Heroin Common Names: H, horse, junk, snow, stuff, lady, dope, shill, pippu, smack, scag, black tar, Lady Jane, white stuff, brown sugar, skunk, white horse^{7,8}

Morphine Common Names: M, dreamer, sweet Jesus, Monkey, morph, White Stuff, Miss Emma^{7,8}

Methadone Common Names: Dolophine, Metadol, Methadose⁷

Codeine Common Names: Robitussin A-C, Tylenol with Codeine, Syrup, schoolboy, 3s, 4s, Captain Cody, Cody^{7,8}

Hydromorphone Common Names: Drug Store Heroin, Hospital Heroin, juice, dillies^{7,8}

Oxycodone Common Names: percs, OC, OXY, oxycotton, killers^{7,8}



Characteristics (Depressant)

Half-life varies depending on the substance. Morphine, Hydromorphone, Oxycodone and Hydrocodone have a half-lives of about 2-3 hours³.

Heroin⁷

- Diacetylmorphine-synthetic derivative of morphine
- Effects are almost immediate following IV injection and can last several hours; effects occur in 15-50min after oral dosing
- Physical dependence and tolerance can occur within two weeks

Morphine⁷

- Effects as for heroin but slower onset and longer-acting
- Effects occur in 15-60min after oral dosing and last 1-8hours for immediate-release products
- High dependence liability due to powerful euphoric and analgesic effects

Methadone⁷

- Effects occur in 30-60minutes after oral dosing and last 7-48hours

Codeine⁷

- Codeine must be metabolized to its active metabolite, morphine for its therapeutic effect.

Fentanyl⁷

- Effects are almost immediate following IV injection and last 30-60 minutes; with IM use, onset is slower and duration of action is up to 120min
- Exposing applied patches to external heat source can increase drug absorption

Hydromorphone⁷

- At low doses, side effects are less common than with other narcotics; at high doses it is more toxic due to strong respiratory depressant effect

Oxycodone⁷

- Very high abuse potential

Carfentanil¹²

- 100x more potent than fentanyl and used in veterinary medicine as a sedative or anesthetic agent for large animals

Presentation during intoxication

Common signs and symptoms of intoxication can include^{1,2}

| | | |
|------------|--------------------|--------------------|
| Euphoria | Lack of motivation | Constricted pupils |
| Drowsiness | Lethargy | |

Extreme intoxication (overdose) signs and symptoms may include²:

| | | |
|-----------------|--------------------|--------------------|
| Slow pulse | Shallow breathing | Respiratory arrest |
| Convulsions | Clammy skin | Constricted pupils |
| Pulmonary edema | Extreme drowsiness | |

| | | | | | | | | | | | | | | | | | | | | | | |
|--|--|---|---------|----------|------------|------------|--|--------------|--------------|----------|---------|------------------|--------------------|--------|----------|----------|----------------|--------------|-------------------|-------------|--------------|---|
| <p>Monitoring and support during intoxication</p> <p>Monitoring and support during intoxication <i>(Continued)</i></p> | <p>Goal¹⁰</p> <ul style="list-style-type: none"> Prevent severe respiratory depression and preserve client safety <p>Monitor¹⁰</p> <ul style="list-style-type: none"> Assess level of disorientation and if possible time of last ingestion and amount consumed Monitor for falls risk Monitor vitals every 15 minutes initially and less frequently as acute symptoms subside <p>If Overdose</p> <ul style="list-style-type: none"> Naloxone (opioid antagonist) is used to reverse the effects of opiate toxicity. In the presence of physical dependence, Naloxone produces withdrawal symptoms related to the dose of Naloxone and the degree and type of opioid dependence. If administered IV, the effect is generally apparent within two minutes. When administered IM, the effect is more prolonged. | | | | | | | | | | | | | | | | | | | | | |
| <p>Withdrawal presentation (onset is usually 8-12 hours after last use of short-acting opioids, for longer acting opioids, withdrawal usually starts 1-3 days after last use)</p> | <p>Mild withdrawal symptoms may include: ^{7,8}</p> <table border="0"> <tr> <td>Watery eyes</td> <td>Yawning</td> <td>Sweating</td> </tr> <tr> <td>Goosebumps</td> <td>Runny nose</td> <td></td> </tr> </table> <p>Moderate to severe withdrawal symptoms: ^{7,8}</p> <ul style="list-style-type: none"> Severe symptoms peak between 48 and 72 hours. Symptoms decrease in 7-10 days for short acting opioids. Methadone withdrawal symptoms can last several weeks. <table border="0"> <tr> <td>Restlessness</td> <td>Irritability</td> <td>Insomnia</td> </tr> <tr> <td>Anxiety</td> <td>Loss of Appetite</td> <td>Abdominal cramping</td> </tr> <tr> <td>Nausea</td> <td>Vomiting</td> <td>Diarrhea</td> </tr> <tr> <td>Muscle tremors</td> <td>Drug Craving</td> <td>Severe Depression</td> </tr> <tr> <td>Tachycardia</td> <td>Hypertension</td> <td>Chills alternating with flushing and sweating</td> </tr> </table> | Watery eyes | Yawning | Sweating | Goosebumps | Runny nose | | Restlessness | Irritability | Insomnia | Anxiety | Loss of Appetite | Abdominal cramping | Nausea | Vomiting | Diarrhea | Muscle tremors | Drug Craving | Severe Depression | Tachycardia | Hypertension | Chills alternating with flushing and sweating |
| Watery eyes | Yawning | Sweating | | | | | | | | | | | | | | | | | | | | |
| Goosebumps | Runny nose | | | | | | | | | | | | | | | | | | | | | |
| Restlessness | Irritability | Insomnia | | | | | | | | | | | | | | | | | | | | |
| Anxiety | Loss of Appetite | Abdominal cramping | | | | | | | | | | | | | | | | | | | | |
| Nausea | Vomiting | Diarrhea | | | | | | | | | | | | | | | | | | | | |
| Muscle tremors | Drug Craving | Severe Depression | | | | | | | | | | | | | | | | | | | | |
| Tachycardia | Hypertension | Chills alternating with flushing and sweating | | | | | | | | | | | | | | | | | | | | |
| <p>Monitoring and support during withdrawal</p> | <p>Goal: ⁷</p> <ul style="list-style-type: none"> Treat the immediate withdrawal reaction <p>Assessing for Withdrawal Severity: ⁵</p> <ul style="list-style-type: none"> May use the Clinical Opiate Withdrawal Scale (COWS) <p>Monitor: ⁵</p> <ul style="list-style-type: none"> Mental Status (Including anxiety, irritability, suicidal ideation) Physical status (including vital signs, sweating, pupil size, GI distress, bone or joint aches, tremors, gooseflesh skin, hydration, sleep patterns) <p>Supportive Interventions: ¹²</p> <ul style="list-style-type: none"> Encourage fluids as tolerated to maintain hydration Provide supportive care and reassurance <p>Commonly used medications include: ⁶</p> <ul style="list-style-type: none"> NSAIDs for myalgias, headache, and fever Dimenhydrinate for nausea and vomiting Loperamide for diarrhea and abdominal cramps Benzodiazepines for acute anxiety Hypnotics for sleep disturbances Clonidine for managing the autonomic symptoms of opioid withdrawal (i.e. hypertension and tachycardia). Methadone/Buprenorphine to treat the immediate withdrawal reaction, and to aid in detoxification, or for maintenance therapy in a supervised treatment program. | | | | | | | | | | | | | | | | | | | | | |

| | |
|---|---|
| <p>Potential Complications</p> | <ul style="list-style-type: none"> • Chronic use can lead to general loss of energy, ambition, and drive, motor retardation, attention impairment, sedation, and slurred speech ⁷ • Chronic use of methadone can lead to constipation, blurred vision, sweating, decreased libido, menstrual irregularities, joint and bone pain, and sleep disturbances⁷ • High doses of fentanyl can produce muscle rigidity (including respiratory muscles) respiratory depression, unconsciousness, and coma ⁷ |
| <p>Notable Drug interactions</p> | <p>With Antidepressants (MAOI, RIMA):²</p> <ul style="list-style-type: none"> • Increased excitation, sweating, and hypotension reported (especially with meperidine, pentazocine); may lead to development of encephalopathy, convulsions, coma, respiratory depression, and serotonin syndrome <p>With Cocaine:⁷</p> <ul style="list-style-type: none"> • May potentiate cocaine euphoria • Cocaine and heroin result in increased dopamine release, which has been associated with an increased risk of death ¹² • Increase the risk and/or intensity of seizure activity ¹² • Cocaine enhances the toxicity of heroin <p>With Alcohol:⁷</p> <ul style="list-style-type: none"> • Additional CNS effects • Caution with excessive doses to risk of respiratory depression • Speeds the release of some opioids into the bloodstream by dissolving the slow-release system <p>Poly-substance use:⁶</p> <ul style="list-style-type: none"> • Combination of alcohol, benzodiazepines and opioids cause CNS depression and possible death. <p>With Cannabis:⁷</p> <ul style="list-style-type: none"> • THC blocks excitation produced by morphine |
| <p>Psychiatric effects</p> | <ul style="list-style-type: none"> • Opiate dependence has been associated with greater incidences of depression, anxiety, suicidal ideation, and low self-esteem¹¹. |

References

1. Publishers Group West. (2015). *Streetdrugs: a drug identification guide*. Long Lake: Publishers group West, LLC.
2. Townsend, M. C. (2015). *Psychiatric Nursing: Assessment, Care, Plans, and Medications*. Philadelphia: F. A Davis Company
3. Fine, G. P. and Portenoy, R. K. (2004). *A Clinical Guide to Opioid Analgesia*. Minneapolis: Healthcare Information Programs.
4. Queensland Government. (2012). *Queensland Alcohol and Drug Withdrawal Clinical Practice Guidelines*. Retrieved on Feb 13, 2015, from http://www.dovetail.org.au/insight/modules/qh_detox_guide.pdf
5. Tompkins, D. A., Bigelow, G. E., Harrison, J. A., Johnson, R. E., Fudala, P. J., & Strain, E. C. (2009). Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. *Drug and alcohol dependence*, 105(1), 154-159.
6. Centre for Addiction and Mental Health, & St. Joseph's Health Centre Toronto. (2011). *Opioid misuse and addiction toolkit*. Retrieved February 10, 2015 from <https://www.porticonetwork.ca/web/opioid-toolkit/treatment/opioid-withdrawal>
7. Bezchlibnyk-Butler, K., Jeffries, J., Procyshyn, R., Virani, A. (2014). *Clinical Handbook of Psychotropic Drugs* (20th ed). Toronto: Hogrefe Publishing
8. Drug Enforcement Administration (2011). *Drugs of Abuse*. Retrieved on February 12, 2015, from http://www.dea.gov/docs/drugs_of_abuse_2011.pdf
9. Boyd, M (2012). *Psychiatric Nursing Contemporary Practice* (5th ed). Wolters Kluwer health/Lippincott Williams and Wilkins.
10. Townsend, M.C. (2015). *Psychiatric Nursing: Assessment, Care Plans, and Medications*. Oklahoma: F.A. Davis Company.
11. Skinner, W., Herie, M., & Mate, G. (2013). *Fundamental of Addiction: A Practical Guide for Counsellors*. Toronto: Centre for Addiction and Mental Health.
12. Winnipeg Regional Health Authority. (n.d.). *A Health Care Provider's Guide to Carfentanil - province of Manitoba*. A Health care provider's guide to Carfentanil. <https://www.gov.mb.ca/health//publichealth/docs/health-care-guide-carfentanil.pdf>